PORTFOLIO NEWS Escient Pharmaceuticals Launches with $40 Million Series A Financing to Advance First-in-Class G Protein-Coupled Receptor (GPCR)-Targeted Drugs to Address Serious, Unserved Medical Needs May 9, 2018 Read More » Nurix Appoints Nancy Pryer, Ph.D., Chief Development Officer May 8, 2018 Read More » ORIC Has Appointed Jacob Chacko, MD as Chief Executive Officer May 7, 2018 Read More » REVOLUTION Medicines Raises $56 Million Series B Financing at $1.50 per share April 24 2018 Read More » eFFECTOR Presents Data on the Discovery and Structure of eFT226, a Novel Inhibitor of eIF4A, at the AACR 2018 Annual Meeting April 16, 2018 Read More » Constellation Pharmaceuticals Announces $100 Million Financing at $1.00 per share April 9, 2018 Read More » Surrozen Strengthens Leadership Team with Addition of Craig Parker as New CEO and Hans Clevers as Scientific Co-founder April 4, 2018 Read More » Arcus Biosciences Announces Pricing of Initial Public Offering at $15 per share March 14, 2018 Read More » Kallyope Announces $66M Series B Financing at $2.00 per share to Advance Programs Targeting the Gut-Brain Axis February 22, 2018 Read More » Aragon’s Drug ARN509 (Now Johnson&Johnson’s Erleada) Gets Quick Push Over the Finish Line by the FDA, with First-Ever Non-Metastatic Prostate Cancer Nod February 15, 2018 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Next »
Escient Pharmaceuticals Launches with $40 Million Series A Financing to Advance First-in-Class G Protein-Coupled Receptor (GPCR)-Targeted Drugs to Address Serious, Unserved Medical Needs May 9, 2018 Read More »
REVOLUTION Medicines Raises $56 Million Series B Financing at $1.50 per share April 24 2018 Read More »
eFFECTOR Presents Data on the Discovery and Structure of eFT226, a Novel Inhibitor of eIF4A, at the AACR 2018 Annual Meeting April 16, 2018 Read More »
Constellation Pharmaceuticals Announces $100 Million Financing at $1.00 per share April 9, 2018 Read More »
Surrozen Strengthens Leadership Team with Addition of Craig Parker as New CEO and Hans Clevers as Scientific Co-founder April 4, 2018 Read More »
Arcus Biosciences Announces Pricing of Initial Public Offering at $15 per share March 14, 2018 Read More »
Kallyope Announces $66M Series B Financing at $2.00 per share to Advance Programs Targeting the Gut-Brain Axis February 22, 2018 Read More »
Aragon’s Drug ARN509 (Now Johnson&Johnson’s Erleada) Gets Quick Push Over the Finish Line by the FDA, with First-Ever Non-Metastatic Prostate Cancer Nod February 15, 2018 Read More »
